Connect with us

Technology

HealthVerity recognized in three 2023 Gartner® Hype Cycle™ reports

Published

on

Recognized for Life Science Clinical Development, Life Science Commercial Operations, and Healthcare Data, Analytics and AI 

PHILADELPHIA, Feb. 13, 2024 /PRNewswire/ — HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced that it was recognized in three of the July 2023 Gartner Hype Cycles titled: Hype Cycle for Life Science Clinical Development, 2023, Hype Cycle for Life Science Commercial Operations, 2023, and Hype Cycle for Healthcare Data, Analytics and AI, 2023. This is the second year in a row that the company has been recognized in all three of these Hype Cycles and the third consecutive year for Life Science Commercial Operations.

HealthVerity was recognized as a vendor providing several different technology solutions in each of the three Hype Cycles:

Life Science Clinical DevelopmentPatient data tokenization – According to Gartner, “Patient data tokenization is the process by which clinical trial subjects/patients consent to have their anonymized health information linked to a subject identifier or token. The token can also be linked to existing real-world data (RWD) sources like healthcare claims and laboratory results. This enables life science companies to link patients who have consented to their retrospective RWD, following their activities prospectively for ongoing insights about branded treatments on patient health.” The Gartner report found that this technology is important because, “Patient data tokenization (PDT) enables patient data to be connected between different data sources, enabling life science companies to formulate a holistic, longitudinal view of the patient journey. RWD made available via tokenization can provide significant insight about patient health history, enabling insights about outcomes after a trial, intervention or treatment has been administered by a life science company.” 

RWD-based trials – “Real-world data (RWD)-based trials use RWD to optimize trial activities with applications that deliver improvements to patient recruitment and retention, protocol optimization, trial feasibility, and safety signal detection. As RWD becomes more available, life science companies and vendors are leveraging it to support effective protocol design, precision methods of finding subjects to successfully complete the trial, and improved data capture that leverages patient health records.”

Data monetization in HCLS – “Data monetization is a practice adopted by a healthcare and life science (HCLS) organization by which they make their proprietary data available to sell to external parties. The most mature examples are payers selling deidentified medical claims data to life science companies. This profile tracks monetization of new data types, utilizing new sharing mechanisms and vendors, targeted at new use cases, which are driving a new cycle of data monetization initiatives.” 

Life Science Commercial OperationsRWD curation and analytics platforms – According to Gartner, “This technology combines real-world data (RWD), such as electronic health records (EHR), medical and prescription claims, disease and patient registries, lab results, imaging and other sources, to provide a longitudinal view of a patient journey. The platform prepares data for delivery to downstream consumption platforms, applications and analytics. It automates the ingestion and linking of data from permissioned sources, manages identity, compliance and security.”

Healthcare Data, Analytics and AIData sharing in HCLS – “Data sharing in healthcare and life science (HCLS) reflects a broad range of use cases that knit together ecosystem partners to advance clinical care, research and discovery; improve public health; decrease health disparities; and lower costs. Data sharing in HCLS relies on a foundation of interoperability, privacy protecting policies and standards to enable the industry to safely and collaboratively drive new value streams through better data sharing partnerships.”

Data monetization in HCLS – Defined by Gartner as, “a practice adopted by a healthcare and life science (HCLS) organization by which they make their proprietary data available to sell to external parties. The most mature examples are payers selling deidentified medical claims data to life science companies. This profile tracks monetization of new data types, utilizing new sharing mechanisms and vendors, targeted at new use cases, which are driving a new cycle of data monetization initiatives.”

HealthVerity offers patient data tokenization services with HealthVerity Identity Manager, a leading patient matching and identity resolution technology that is 10x more accurate than legacy tokenization technologies. Identity Manager establishes a unique but persistent HealthVerity ID (HVID) to resolve patient identity over time and across data sources to create a fully interoperable single source of truth. HealthVerity FLOW is a middleware solution that can enable RWD-based clinical trials and be used as a RWD curation and analytics platform that leverages this source of truth capability to enable RWD-driven patient journey initiatives. For example, the platform can synchronize clinical trial participants, their permissions, and the broadest set of identifiable and de-identified data sources in a fully governed, HIPAA-compliant manner to accelerate the time to FDA submission. Additionally, HealthVerity offers data owners the ability to join the nation’s largest healthcare and consumer data ecosystem while managing all aspects of identity resolution, privacy protection and governance of data usage rights for the seamless exchange of unlimited real-world data on HealthVerity Marketplace.

“We are excited to be recognized by Gartner in the Hype Cycle reports,” said HealthVerity COO Andrew Goldberg. “We pride ourselves on offering the life sciences and healthcare sectors transformational technologies that synchronize unparalleled identity management with built-in privacy compliance and governance of data usage rights for the seamless exchange of a near limitless combination of healthcare and consumer data. We believe our inclusion in the Gartner Hype Cycle reports demonstrates the difference these solutions can have on advancing the science.”

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

Gartner Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About HealthVerity
HealthVerity synchronizes transformational technologies with the nation’s largest healthcare and consumer data ecosystem to power previously unattainable outcomes and fundamentally advance the science. We offer a comprehensive, yet flexible approach, based on the foundational elements of Identity, Privacy, Governance and Exchange (IPGE), that synchronizes unparalleled Identity management with built-in Privacy compliance and Governance, providing the ability to discover and Exchange a near limitless combination of data at a record pace. Together with our partners in life sciences, government and insurance, we are Synchronizing the Science. To learn more about HealthVerity, visit healthverity.com.

HealthVerity Contact:
Colleen Stoker
614-738-0592
cstoker@healthverity.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/healthverity-recognized-in-three-2023-gartner-hype-cycle-reports-302059926.html

SOURCE HealthVerity

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

iFOREX Lists on London Stock Exchange, Supporting Focus Across Global and Indian Markets

Published

on

By

LONDON, April 17, 2026 /PRNewswire/ — iFOREX today announced its recent admission to the Main Market of the London Stock Exchange (LSE) under the ticker IFRX, at a market valuation of approximately £43.3 million. This milestone marks a significant step in the Company’s long-term growth strategy and supports its continued expansion across international markets, including a growing focus on India.

With over 30 years of experience in the online trading industry, iFOREX has established a strong global presence built on proprietary technology, consistent innovation, and disciplined risk management. The Company continues to deliver advanced trading solutions alongside a high standard of client support, designed to meet the evolving needs of retail traders in dynamic markets.

Through its proprietary web-based and mobile trading platforms, iFOREX provides access to over 900 financial instruments, including foreign exchange, commodities, indices, stocks, cryptocurrencies, and ETFs. The Company continuously enhances its technology and product offering to deliver a seamless, secure, and efficient trading experience for its global client base.

India represents an increasingly important market for iFOREX, supported by a rapidly growing base of digitally engaged traders and rising interest in global financial markets. The Company aims to strengthen its presence by offering localized support, tailored educational resources, and technology-driven solutions aligned with the needs of Indian traders.

The Company’s admission to the London Stock Exchange enhances its visibility and credibility as a global fintech provider, focusing on investing in platform development, optimizing client experience, and scaling its international operations to support long-term growth.

“Our listing on the London Stock Exchange represents an important milestone in iFOREX’s evolution as a global trading provider,” said Itai Sadeh, Chief Executive Officer of iFOREX. “We see significant potential in the Indian market, driven by strong demand for digital trading solutions and increasing participation in global markets. We remain committed to expanding our presence in India while continuing to invest in technology, innovation, and client experience.”

iFOREX will continue to monitor market developments, adapt its offering to the needs of traders across different regions, and focus on delivering reliable services, transparent trading conditions, and long-term value to its clients and stakeholders.

Find out more here: iFOREX Website

This press release is intended solely for media use. It is not meant for individual investors and does not contain personal advice or recommendations.

 

View original content:https://www.prnewswire.com/in/news-releases/iforex-lists-on-london-stock-exchange-supporting-focus-across-global-and-indian-markets-302755696.html

Continue Reading

Technology

iFOREX Lists on London Stock Exchange, offering Cryptocurrency trading (CFDs) Across Global and LATAM Markets

Published

on

By

LONDON, April 29, 2026 /PRNewswire/ — iFOREX today announced its admission to the Main Market of the London Stock Exchange (LSE) under the ticker IFRX, with a market valuation of approximately £43.3 million. This milestone represents a major step in the Company’s global growth strategy and supports its continued expansion across international markets, including cryptocurrency CFD trading for retail investors in Latin America (LATAM) and beyond.

The listing underscores iFOREX’s commitment to combining traditional financial instruments with the evolving opportunities presented by the cryptocurrency market. Over the past decade, iFOREX has offered retail traders access to a broad portfolio of crypto CFDs, including Bitcoin (BTC), Ethereum (ETH), Ripple (XRP), Litecoin (LTC), and a growing range of other digital assets, alongside forex, commodities, indices, equities, and ETFs. The Company’s proprietary online and mobile platforms allow traders to seamlessly navigate both crypto and traditional markets from a single interface.

With more than 25 years of experience in online trading, iFOREX has built a solid global presence based on proprietary technology, disciplined risk management, and continuous innovation. By integrating crypto trading alongside traditional instruments, the Company provides traders with diversified opportunities, enhanced liquidity, and sophisticated tools to manage risk and capitalize on market trends.

Latin America represents a particularly high-growth region for cryptocurrency trading, supported by increasing digital adoption, rising interest in global financial markets, and a growing number of self-directed retail investors. iFOREX is committed to strengthening its presence in the region by offering localized services, multilingual support, and educational resources specifically designed to help LATAM clients engage confidently with both crypto and forex markets.

The LSE listing enhances iFOREX’s credibility and visibility as a global fintech provider while supporting its strategy to expand crypto trading offerings, scale operations, and provide long-term value to clients and shareholders. The Company continues to focus on platform innovation, regulatory compliance, and the development of tools that allow traders to execute informed and secure transactions across all available markets.

Itai Sadeh, Chief Executive Officer of iFOREX, commented:

“Our admission to the Main Market of the London Stock Exchange represents a landmark moment for iFOREX and reflects our commitment to innovation in financial trading, including cryptocurrencies. Latin America presents strong growth potential in digital assets, and we are focused on providing robust, reliable platforms, localized education, and tools that empower traders to access opportunities across both crypto and traditional markets.”

Looking forward, iFOREX plans to expand its crypto product offering, explore emerging digital asset trends, and continue delivering a secure, innovative, and client-focused trading experience to retail investors worldwide.

 

View original content:https://www.prnewswire.co.uk/news-releases/iforex-lists-on-london-stock-exchange-offering-cryptocurrency-trading-cfds-across-global-and-latam-markets-302755709.html

Continue Reading

Technology

Temu and QIMA Partner to Strengthen Product Testing and Platform Compliance

Published

on

By

DUBLIN, April 29, 2026 /PRNewswire/ — Temu, the global e-commerce platform, and QIMA, a leading testing, inspection, and certification company, today announced a partnership to strengthen product compliance and safety across the Temu platform. Under the partnership, QIMA’s testing and certification services will be integrated directly into Temu’s Seller Center, making compliance resources accessible to sellers.

QIMA will deliver independent product testing, on-site factory inspections, seller training programs, and digital compliance tools. Product testing will cover four initial categories: electrical and electronic goods, jewelry and gemstones, food contact materials, and light industrial products. Testing will be conducted against applicable regulatory and safety standards. QIMA will also conduct on-site factory inspections for selected sellers to verify production processes and supply chain practices at the source.

The Temu-QIMA partnership also includes structured training programs designed to help sellers better understand testing standards and regulatory requirements across markets, along with regular roundtables and workshops on evolving rules, policy developments, and compliance approaches.

“As e-commerce platforms serve more markets and more product categories, independent compliance infrastructure becomes essential, not optional,” said Pierre-Nicolas Disser, CEO of Consumer Products, QIMA. “This partnership, and particularly the integration into Temu’s Seller Center, is a step toward making compliance testing and certification a routine part of how sellers operate. That’s exactly the kind of work QIMA’s global network was built for.”

The partnership with QIMA builds on Temu’s broader product safety and compliance program. In 2025, the company invested approximately US$100 million globally in compliance, product safety, and quality control, with plans to double that investment in 2026. To date, Temu has established cooperation with more than 60 independent testing institutions worldwide. The partnership with QIMA represents one of the first integration of third-party compliance tools directly into the Temu Seller Center workflow.

“Temu prioritizes the safety of products on our platform, and our partnership with QIMA is a concrete step in that direction,” said a Temu spokesperson. “Together with QIMA, we are focused on providing consumers with a safe and trustworthy shopping experience, while making compliance resources more accessible to sellers on our platform.”

About Temu

Temu is a global e-commerce platform connecting consumers with millions of manufacturers, brands, and business partners. Operating in more than 90 markets worldwide, Temu is committed to providing affordable, high-quality products that enable customers to live better lives.

About QIMA

At QIMA, we are on a mission to help our clients make products consumers can trust. We have developed compliance solutions for testing, inspection and certification (TIC) that enable supply chain agility, sustainability, and product innovation. Our services are used by 30,000 businesses globally in the consumer products, agri-food and life sciences industries. What truly sets us apart is our unique culture of relentless care for our clients, and a commitment to offering intuitive solutions that blend deep tech and human intelligence; this is how QIMA continues to disrupt the Testing, Inspection and Certification industry.

SOURCE Temu

Continue Reading

Trending